title: [Primary hormone treatment of early endometrial cancer].
abstract: Six cases of primary treated endometrial cancer are included in this research work. Five of these women ended with tumour regression and 2 with pregnancies and deliveries of children. All of the women are still alive without having disease with mean follow-up period of 36.5 months (from 16 to 80 months). We consider that this is very promising method of treatment to offer y conservative treatment with high level of survival and possibility for having y child. Diagnostic and therapeutic data for the patients who are with early endometrial cancer and wish to have y child are analyised in this study. Four of the women were treated with GnRh-analogs-Zoladex and 2 with progestins-high doses.
authors.forename: S
authors.initials: S
authors.lastname: Ivanov
authors.forename: S
authors.initials: S
authors.lastname: Ivanov
authors.forename: T
authors.initials: T
authors.lastname: Kŭrlov
authors.forename: A
authors.initials: A
authors.lastname: Milev
authors.forename: S
authors.initials: S
authors.lastname: Kulander
authors.forename: V
authors.initials: V
authors.lastname: Ivanov
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011372:Progestins / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone